UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM SD
Specialized Disclosure Report
Specialized Disclosure Report
![livanova2017conflictm_image1.jpg](https://capedge.com/proxy/SD/0001639691-18-000058/livanova2017conflictm_image1.jpg)
LivaNova PLC
England and Wales (State or other jurisdiction of incorporation or organization) | 001-37599 (Commission File Number) | 98-1268150 (I.R.S. Employer Identification No.) |
20 Eastbourne Terrace
London, United Kingdom
W2 6LG
(Address of Principal Executive Offices) (Zip Code)
Catherine Moroz
Company Secretary
+44 (0)203 786 5277
(Name and telephone number, including area code, of the person to contact in connection with this report)
Check the appropriate box to indicate the rule pursuant to which this form is being filed,
and provide the period to which the information in this form applies:
and provide the period to which the information in this form applies:
x | Rule 13p-1 under the Securities Exchange Act (17 CFR 240.13p-1) for the reporting period from January 1 to December 31, 2017. |
INFORMATION TO BE INCLUDED IN THE REPORT
Section 1—Conflict Minerals Disclosure
Item 1.01 Conflict Minerals Disclosure and Report
LivaNova PLC, a public limited company incorporated under the laws of England and Wales (“LivaNova”) was formed for the purpose of facilitating the business combination of Cyberonics, Inc., a Delaware corporation (“Cyberonics”), and Sorin S.p.A., a joint stock company organized under the laws of Italy (“Sorin”). Cyberonics was considered the accounting acquirer and LivaNova PLC (“LivaNova”, “registrant”, “we”, “us”, or “our”) became the successor organization to Cyberonics. This report combines the reporting requirements for legacy Cyberonics and now also includes reporting requirements for those products previously manufactured and distributed by legacy Sorin S.p.A. LivaNova is filing this Specialized Disclosure report on Form SD (this “Form SD”) for LivaNova’s Neuromodulation, Cardiac Rhythm Management, and Cardiac Surgery supply chain operations for the year ended December 31, 2017. This Form SD is presented in compliance with Rule 13p-1 under the Securities Exchange Act of 1934, as amended, for the reporting period from January 1, 2017 to December 31, 2017.
A copy of our Conflict Minerals Report is filed as a part of this Form SD. In accordance with Rule 12b-12 (17 CFR 240.12b-12), a copy of this Form SD may be found on our website at http://www.livanova.com/investor-relations/sec-filings.
Item 1.02 Exhibits
LivaNova has filed, as an exhibit to this Form SD, the Conflict Minerals Report required by Item 1.01.
Section 2—Exhibits
Item 2.01 Exhibits
The following exhibit is filed as part of this report.
Exhibit | Description | |
1.01 | Conflict Minerals Report as required by Items 1.01 and 1.02 of this Form. |
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the duly authorized undersigned.
LivaNova PLC | |
Date: May 31, 2018 | By:/s/ Catherine Moroz |
Name: Catherine Moroz | |
Title: Company Secretary | |
3